Applied Therapeutics Inc

Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company which engages in the development of a pipeline of novel products. It is targeting treatments for central nervous system rare diseases and diabetic complications. The company was founded by Shoshana Shendelman on January 20, 2016 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK, NY / ACCESSWIRE / December 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Applied Therapeutics, Inc. ("Applied Therapeutics, Inc.") (NASDAQ:APLT) concerning possible violations of federal securities laws. Applied Therapeutics issued a press release on November 27, 2024, announcing "that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for govorestat, a novel, central nervous system (CNS)-penetrant aldose reductase inhibitor (ARI), for the treatment of Classic Galactosemia.

Applied Therapeutics, Inc. Being Investigated on Behalf of Applied Therapeutics, Inc. Investors. Contact Levi & Korsinsky For Details.

NEW YORK, NY / ACCESSWIRE / December 12, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Applied Therapeutics, Inc. ("Applied Therapeutics" or "the Company") (NASDAQ:APLT). Investors who purchased Applied Therapeutics securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/APLT.

Applied Therapeutics, Inc. (APLT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Applied Therapeutics, Inc. (“Applied Therapeutics” or the “Company”) (NASDAQ: APLT) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On November 27, 2024, Applied Therapeutics disclosed that it had received a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration (.

The Law Offices of Frank R. Cruz Announces Investigation of Applied Therapeutics, Inc. (APLT) on Behalf of Investors

NEW YORK, NY / ACCESSWIRE / December 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Applied Therapeutics, Inc. ("Applied Therapeutics, Inc.") (NASDAQ:APLT) concerning possible violations of federal securities laws. Applied Therapeutics issued a press release on November 27, 2024, announcing "that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for govorestat, a novel, central nervous system (CNS)-penetrant aldose reductase inhibitor (ARI), for the treatment of Classic Galactosemia.

Applied Therapeutics, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - APLT

ATTENTION Applied Therapeutics, Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights

NEW YORK, NY / ACCESSWIRE / December 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Applied Therapeutics, Inc. ("Applied Therapeutics" or "the Company") (NASDAQ:APLT). Investors who purchased Applied Therapeutics securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/APLT.

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Applied Therapeutics, Inc. (APLT) and Encourages Stockholders to Learn More About the Investigation

NEW YORK, NY / ACCESSWIRE / December 10, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Applied Therapeutics, Inc. ("Applied Therapeutics, Inc.") (NASDAQ:APLT) concerning possible violations of federal securities laws. Applied Therapeutics issued a press release on November 27, 2024, announcing "that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for govorestat, a novel, central nervous system (CNS)-penetrant aldose reductase inhibitor (ARI), for the treatment of Classic Galactosemia.

Shareholder Rights Advocates at Levi & Korsinsky Investigate Applied Therapeutics, Inc. (APLT) Regarding Possible Securities Fraud Violations

NEW YORK, NY / ACCESSWIRE / December 10, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Applied Therapeutics, Inc. ("Applied Therapeutics" or "the Company") (NASDAQ:APLT). Investors who purchased Applied Therapeutics securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/APLT.

Bronstein, Gewirtz & Grossman, LLC Encourages Applied Therapeutics, Inc. (APLT) Investors to Inquire about Securities Investigation

Lost Money on Applied Therapeutics, Inc.(APLT)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky

NEW YORK CITY, NY / ACCESSWIRE / December 10, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Applied Therapeutics, Inc. ("Applied Therapeutics" or "the Company") (NASDAQ:APLT). Investors who purchased Applied Therapeutics securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/APLT.

Applied Therapeutics, Inc. (APLT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

NEW YORK, NY / ACCESSWIRE / December 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Applied Therapeutics, Inc. ("Applied Therapeutics, Inc.") (NASDAQ:APLT) concerning possible violations of federal securities laws. Applied Therapeutics issued a press release on November 27, 2024, announcing "that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for govorestat, a novel, central nervous system (CNS)-penetrant aldose reductase inhibitor (ARI), for the treatment of Classic Galactosemia.

ATTENTION APLT SHAREHOLDERS: Investors who lost money on Applied Therapeutics, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation

NEW YORK CITY, NY / ACCESSWIRE / December 9, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Applied Therapeutics, Inc. ("Applied Therapeutics" or "the Company") (NASDAQ:APLT). Investors who purchased Applied Therapeutics securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/APLT.

Bronstein, Gewirtz & Grossman, LLC Encourages Applied Therapeutics, Inc. (APLT) Shareholders to Inquire about Securities Investigation

NEW YORK, NY / ACCESSWIRE / December 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Applied Therapeutics, Inc. ("Applied Therapeutics, Inc.") (NASDAQ:APLT) concerning possible violations of federal securities laws. Applied Therapeutics issued a press release on November 27, 2024, announcing "that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for govorestat, a novel, central nervous system (CNS)-penetrant aldose reductase inhibitor (ARI), for the treatment of Classic Galactosemia.

Applied Therapeutics, Inc. (APLT) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates

NEW YORK, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Wolf Popper LLP is investigating potential claims on behalf of purchasers of Applied Therapeutics, Inc. (“Applied Therapeutics”) common stock (NASDAQ: APLT). Applied Therapeutics is a clinical-stage biopharmaceutical company.

Wolf Popper LLP Announces Investigation on Behalf of Applied Therapeutics, Inc. Investors

NEW YORK, NY / ACCESSWIRE / December 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Applied Therapeutics, Inc. ("Applied Therapeutics, Inc.") (NASDAQ:APLT) concerning possible violations of federal securities laws. Applied Therapeutics issued a press release on November 27, 2024, announcing "that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for govorestat, a novel, central nervous system (CNS)-penetrant aldose reductase inhibitor (ARI), for the treatment of Classic Galactosemia.

Investors who lost money on Applied Therapeutics, Inc. should contact Levi & Korsinsky about an ongoing investigation - APLT

NEW YORK, NY / ACCESSWIRE / December 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Applied Therapeutics, Inc. ("Applied Therapeutics, Inc.") (NASDAQ:APLT) concerning possible violations of federal securities laws. Applied Therapeutics issued a press release on November 27, 2024, announcing "that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for govorestat, a novel, central nervous system (CNS)-penetrant aldose reductase inhibitor (ARI), for the treatment of Classic Galactosemia.

Applied Therapeutics, Inc. Being Investigated on Behalf of Applied Therapeutics, Inc. Investors. Contact Levi & Korsinsky For Details

An Investigation Has Commenced on Behalf of Applied Therapeutics, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your APLT Losses.

NEW YORK CITY, NY / ACCESSWIRE / December 5, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Applied Therapeutics, Inc. ("Applied Therapeutics" or "the Company") (NASDAQ:APLT). Investors who purchased Applied Therapeutics securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/APLT.

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Applied Therapeutics, Inc. (APLT) and Encourages Investors to Learn More About the Investigation

NEW YORK, NY / ACCESSWIRE / December 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Applied Therapeutics, Inc. ("Applied Therapeutics, Inc.") (NASDAQ:APLT) concerning possible violations of federal securities laws. Applied Therapeutics issued a press release on November 27, 2024, announcing "that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for govorestat, a novel, central nervous system (CNS)-penetrant aldose reductase inhibitor (ARI), for the treatment of Classic Galactosemia.

APLT ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Applied Therapeutics, Inc. Shareholders Who Lost Money

NEW YORK CITY, NY / ACCESSWIRE / December 4, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Applied Therapeutics, Inc. ("Applied Therapeutics" or "the Company") (NASDAQ:APLT). Investors who purchased Applied Therapeutics securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/APLT.

Applied Therapeutics, Inc. (APLT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

NEW YORK, NY / ACCESSWIRE / December 3, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Applied Therapeutics, Inc. ("Applied Therapeutics, Inc.") (NASDAQ:APLT) concerning possible violations of federal securities laws. Applied Therapeutics issued a press release on November 27, 2024, announcing "that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for govorestat, a novel, central nervous system (CNS)-penetrant aldose reductase inhibitor (ARI), for the treatment of Classic Galactosemia.

Lost Money on Applied Therapeutics, Inc. (APLT)? Contact Levi & Korsinsky Regarding an Ongoing Investigation

Applied Therapeutics said on Monday it received a warning letter limited to a trial studying its genetic disease drug, after the U.S. health regulator declined to approve the treatment last week.

Applied Therapeutics says it received FDA's warning letter for genetic disease drug study

The pharma company's shares are getting crushed after regulators decline to green light a drug to treat a rare disease.

Applied Therapeutics Stock Plummets 73%. The FDA Delivers This Crushing Blow.

Applied Therapeutics (APLT) shares cratered Friday as the biopharmaceutical firm reported that the Food and Drug Administration (FDA) rejected its application for its experimental treatment for a rare metabolic disease known as Galactosemia.

Applied Therapeutics Stock Plummets After FDA Rejects Metabolic Disease Drug

On Wednesday, Applied Therapeutics, Inc APLT received an FDA Complete Response Letter (CRL) for the New Drug Application (NDA) for govorestat for Classic Galactosemia.

News for Applied Therapeutics Inc Stock (APLT)